Todd Harris Sells 15,394 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 15,394 shares of the firm’s stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $25.85, for a total value of $397,934.90. Following the completion of the sale, the chief executive officer now directly owns 1,418,647 shares in the company, valued at approximately $36,672,024.95. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Todd Harris also recently made the following trade(s):

• On Tuesday, October 15th, Todd Harris sold 10,035 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.31, for a total transaction of $243,950.85.
• On Monday, September 30th, Todd Harris sold 500 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.00, for a total value of $12,000.00.
• On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.01, for a total value of $14,406.00.
• On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.13, for a total transaction of $243,519.96.
• On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total transaction of $138,518.38.

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA opened at $27.33 on Friday. The business’s 50-day simple moving average is $22.32 and its 200-day simple moving average is $19.49. Tyra Biosciences, Inc. has a 52 week low of $10.38 and a 52 week high of $27.55. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -16.17 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.09. As a group, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. HC Wainwright raised their target price on Tyra Biosciences from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Oppenheimer raised their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Wedbush reiterated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Thursday, August 8th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $22.00 to $31.00 in a report on Friday. Finally, Piper Sandler assumed coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $31.00.

Hedge Funds Weigh In On Tyra Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. HighVista Strategies LLC bought a new position in Tyra Biosciences in the second quarter worth $257,000. SG Americas Securities LLC bought a new position in shares of Tyra Biosciences during the 3rd quarter worth about $311,000. Rhumbline Advisers boosted its position in shares of Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after acquiring an additional 2,574 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Tyra Biosciences by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after acquiring an additional 14,352 shares during the period. Finally, Oppenheimer & Co. Inc. acquired a new position in Tyra Biosciences in the first quarter worth about $977,000. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.